Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218633 · ClinicalTrials.gov registry record · Phase 1
Dose-response Study of Exendin-9,39 on Glucose Metabolism
A Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01218633: Completed Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1, sponsored by Adrian Vella.
NCT01218633 is a Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 that has completed, run by Adrian Vella. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01218633, a Phase 1 study of Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
Conditions Studied
Interventions
- DRUG saline infusion
- DRUG GLP-1-9,36 infusion
- DRUG Exendin-9,39 at low dose
- DRUG Exendin-9,39 at high dose
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT01218633 record still lists
NCT01218633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 appearing as the primary indexed condition, and to 4 interventions - of which saline infusion is the first listed.
NCT01218633 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01218633 about?
NCT01218633 is a clinical study titled "Dose-response Study of Exendin-9,39 on Glucose Metabolism". Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actio...
What is the current status of trial NCT01218633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-05. Estimated completion is 2012-12.
What conditions does trial NCT01218633 study?
This clinical trial studies the following conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1.
What interventions are being tested in trial NCT01218633?
The interventions under investigation include: saline infusion (DRUG), GLP-1-9,36 infusion (DRUG), Exendin-9,39 at low dose (DRUG), Exendin-9,39 at high dose (DRUG).
Who is sponsoring clinical trial NCT01218633?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01218633 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01218633's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia